Singapore-based company TauRx Therapeutics has selected BioClinica's Trident IWR/IVR solution to use in a series of expanded Phase III trials for its pipeline of neurology treatment candidates.
BioClinica will also be providing Imaging Core Lab (ICL) solutions, which use new technology to efficiently acquire, process, and read medical images, for TauRx Therapeutics' upcoming Phase III clinical trials.
TauRx Therapeutics chief medical officer Dr Jiri Hardlund said the company has chosen Trident IWR to reduce the lead time and effort needed to prepare for its studies, while supporting all of randomization and clinical supplies tracking requirements.
"When we investigated the available technologies, it was clear that Trident offered clear advantages for our trials' requirements," Hardlund added.
TauRx Therapeutics global logistics and support lead Dr Diane Downie said the company believes that BioClinica's MRI imaging solution best matched all of its requirements.
"MRI imaging represents a critical eligibility and safety component of our clinical studies," Downie added.
